CANDACE CHITSAZ: Open Payments
NPI 1447270962 · CARY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 27 payments from 11 companies in 2025. Trend: 2023 $640 · 2024 $428 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $177 |
| Abbott Laboratories | 3 | $58 |
| Amgen Inc. | 3 | $47 |
| PFIZER INC. | 2 | $41 |
| Novo Nordisk Inc | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
Products named: UBRELVY, QULIPTA, CAPLYTA, VRAYLAR, Kerendia, ZEPBOUND, NURTEC ODT, AIRSUPRA.
Industry payments across NC — which companies pay providers there.
